期刊
LEUKEMIA
卷 36, 期 1, 页码 58-67出版社
SPRINGERNATURE
DOI: 10.1038/s41375-021-01341-y
关键词
-
资金
- KiKa
- European Research Council (ERC) [671174]
- European Research Council (ERC) [671174] Funding Source: European Research Council (ERC)
This study identified markers of prednisone-dependent signature in infant acute lymphoblastic leukemia, allowing for better prediction of future relapse by categorizing leukemic cells as treatment resistant or sensitive. The findings also shed light on the characteristics of leukemia cells associated with high relapse risk, improving current risk stratification and understanding of therapy-resistant subpopulations.
Infants with MLL-rearranged infant acute lymphoblastic leukemia (MLL-r iALL) undergo intense therapy to counter a highly aggressive malignancy with survival rates of only 30-40%. The majority of patients initially show therapy response, but in two-thirds of cases the leukemia returns, typically during treatment. The glucocorticoid drug prednisone is established as a major player in the treatment of leukemia and the in vivo response to prednisone monotreatment is currently the best indicator of risk for MLL-r iALL. We used two different single-cell RNA sequencing technologies to analyze the expression of a prednisone-dependent signature, derived from an independent study, in diagnostic bone marrow and peripheral blood biopsies. This allowed us to classify individual leukemic cells as either resistant or sensitive to treatment and show that quantification of these two groups can be used to better predict the occurrence of future relapse in individual patients. This work also sheds light on the nature of the therapy-resistant subpopulation of relapse-initiating cells. Leukemic cells associated with high relapse risk are characterized by basal activation of glucocorticoid response, smaller size, and a quiescent gene expression program with cell stemness properties. These results improve current risk stratification and elucidate leukemic therapy-resistant subpopulations at diagnosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据